Disease · HP_0012332
Abnormal autonomic nervous system physiology
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Abnormal autonomic nervous system physiology. Diseases, record HP_0012332. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012332
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Abnormal autonomic nervous system physiology
- Open Targets ID
- HP_0012332
- Other names
- Autonomic dysfunction, Autonomic dysregulation, Dysautonomia
- Highest stage of its drugs
- Phase 2, for 5 of its 8 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 2 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets | |
| IVABRADINE | CHEMBL471737 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SALSALATE | CHEMBL154111 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AMIFAMPRIDINE | CHEMBL354077 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| VERAPAMIL | CHEMBL6966 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALPRAZOLAM | CHEMBL661 | Small molecule | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GLUCAGON-LIKE PEPTIDE 1 | CHEMBL4594475 | Protein | Early phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CARVEDILOL | CHEMBL723 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets67
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 1 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| ADRB1 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/154 | Drugs and targets |
| ADRB3 | Adrenergic receptor beta | 1 | Adrenergic receptor beta antagonist | Unknown | https://conductscience.org/library/genes/155 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 1 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/779 | Drugs and targets |
1 to 10 of 67
See all 67 targetsTrials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02406586 | Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2) | Not applicable | 36 | 2015-05-28 | Hypertension, Diabetes | CARVEDILOL, SALSALATE | Its record names the disease | ClinicalTrials.gov |
| NCT01977417 | Inflammation Inhibition in Prediabetic Humans | Phase 2 | 21 | 2023-09-11 | Prediabetes, Obese | SALSALATE | Its record names the disease | ClinicalTrials.gov |
| NCT01607073 | Verapamil as Therapy for Children and Young Adults With Dravet Syndrome | Phase 2 | 2 | 2021-03-23 | Dravet Syndrome | VERAPAMIL | Its record names the disease | ClinicalTrials.gov |
| NCT06305780 | RECOVER-AUTONOMIC Platform Protocol | Phase 2 | 381 | Long COVID, Long Covid19, Long Covid-19 | IVABRADINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06305806 | RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) | Phase 2 | 181 | Long COVID, Long Covid19, Long Covid-19 | IVABRADINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01858896 | GLP-1 and Hypoglycemia | Early phase 1 | 28 | Type 2 Diabetes Mellitus | GLUCAGON-LIKE PEPTIDE 1 | Its record names the disease | ClinicalTrials.gov | |
| NCT00574639 | Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2 | Early phase 1 | 14 | Type 1 Diabetes | ALPRAZOLAM | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Salsalate vs Placebo: deaths from any cause | 0 of 8 | 0 of 13 | 21 | NCT01977417 | Trial comparisons |
| Salsalate vs Placebo: serious adverse events | 0 of 8 | 0 of 13 | 21 | NCT01977417 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012332
GET https://conductscience.org/api/diseases/v1/HP_0012332/targets?page=2